Top 10 Best Biomarker Testing Services of 2026

Labcorp supports biomarker testing programs that require consistent analytical execution across multiple specimen types and sites, with documented laboratory processes behind each assay workflow. The provider is a fit for organizations that need high-throughput processing with controlled turnaround from accession to reporting, rather than only bespoke assay design. Coverage includes common clinical assay modalities and pathology-adjacent workflows used in diagnostic and companion settings, which reduces the need to stitch multiple vendors.

A tradeoff is that deeper workflow integration depends on the buyer’s data and ordering environment, so API-driven automation may require governance work at the integration layer. Labcorp fits situations where a pharmaceutical or healthcare network already has a standardized ordering model and wants laboratory execution plus result delivery that downstream teams can ingest with fewer manual steps.

Mayo Clinic Laboratories supports biomarker testing through laboratory-developed and specialty assays that can be ordered as discrete tests in a clinical care pathway. The service is aligned to operational needs like specimen acceptance rules, documented handling, and electronic reporting that reduces rework for care teams. The lab network approach can help institutions reduce vendor fragmentation when multiple biomarker types are ordered through the same clinical laboratory channel.

A key tradeoff is that the service optimizes for clinical laboratory delivery rather than offering a developer-first API for automated assay orchestration. Mayo Clinic Laboratories fits best when workflows are managed by clinical coordinators and ordering systems, not when data ingestion and assay execution must be driven entirely by external automation. A strong usage situation is onboarding a healthcare system that needs consistent specimen handling and interpretation across tumor markers and related companion diagnostic style decisions.

Ambry Genetics provides biomarker testing that centers on genomic variant detection and clinical reporting for oncology use cases that require consistent interpretation and documentation. The operational flow typically begins with specimen chain of custody, proceeds through sequencing or laboratory assay execution, and ends with structured report outputs for clinician review. For teams that need repeatable case handling, the service includes administrative steps for test selection, accessioning, and result release workflows.

A tradeoff is that deeper system integration depends on the specific engagement scope rather than a single universal integration package. Ambry works best when ordering and reporting are managed through defined clinical and laboratory handoffs, and when in-house teams primarily consume results rather than needing custom data model mapping for every field. Usage is strongest for oncology biomarker programs that value interpretation consistency and documented laboratory processes over highly bespoke assay development.

Natera is a biomarker testing service built around clinical-grade molecular testing workflows that support oncology and inherited disease use cases. Its core differentiation is a production pipeline designed for liquid biopsy centered assays and targeted molecular outputs that feed downstream decision-making.

Natera also provides operational controls for specimen handling, result delivery, and report traceability that fit clinical laboratory environments. Integration depth is strongest when ordering systems need repeatable assay execution and consistent electronic result artifacts.

Myriad Genetics delivers clinical biomarker testing built around comprehensive tumor profiling and companion diagnostic style workflows. Core capabilities include NGS-based genomic testing and curated variant interpretation workflows that support decision-relevant outputs for oncology studies and care.

The service experience centers on specimen intake, laboratory processing, and electronic reporting that route results into downstream clinical or research review. Operational fit is strongest for organizations that need managed testing with standardized interpretive artifacts rather than self-administered assay development.

ARUP Laboratories is a biomarker testing service known for deep lab operations and high-complexity assay work. It supports a wide set of specimen-driven clinical biomarker workflows, including molecular and pathology-adjacent testing where chain of custody and result interpretation rigor matter. The practical differentiator is ARUP’s lab-centered integration into clinical programs that need controlled turnarounds, clear reporting artifacts, and consistent test methodologies across sites.

Quest Diagnostics differentiates itself through enterprise-scale laboratory operations and broad clinical test catalog breadth, which supports biomarker testing across many therapeutic areas. Its biomarker workflows center on specimen chain of custody and high-throughput lab processing, which can reduce handoff friction for health systems that already standardize ordering and receiving.

The service is built to integrate with existing clinical ordering and electronic laboratory reporting processes rather than introducing a standalone testing portal. Quest Diagnostics also supports assay workflows spanning common molecular and immuno-based methods used in clinical decision-making.

Foundation Medicine is a clinical biomarker testing service built around tumor genomic profiling and curated interpretation for oncology decision-making. The core capability centers on extracting DNA from tumor tissue or blood and running a panel-based diagnostic biomarker assay with standardized reporting.

Results are delivered with context for variant interpretation and treatment-relevant findings that support consistent downstream workflows. Governance is strengthened through specimen traceability and structured report outputs that integrate into clinical and research operations.

Guardant Health performs liquid biopsy testing that profiles circulating tumor DNA from blood specimens for clinically actionable genomic variants. Core capabilities center on targeted ctDNA assays that support variant detection workflows and downstream clinical interpretation for oncology decision-making.

The service also provides report outputs designed for clinical review and integration into health systems that already consume genomic testing results. Guardant Health’s distinction comes from its focus on blood-based genomic profiling paired with assay-focused operational workflows rather than tissue-only testing.

Exact Sciences delivers biomarker testing tied to oncology diagnostics, with laboratory workflows built around clinically oriented specimen handling and assay execution. The service centers on its established colorectal cancer diagnostics portfolio and expands into broader biomarker needs through its lab operations and test menu approach.

Strength shows in turn-key coordination across specimen logistics, test performance processes, and electronic reporting used by clinical teams. Limitations show up when programs require highly bespoke biomarker panels or deep custom method development outside Exact Sciences’ core diagnostic pathways.